Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omiganan in mild to moderate atopic dermatitis
2014-003689-26Phase 2Completed
- Sponsor
- Biofrontera
- Start
- Apr 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Omiganan topical gel with Placebo (2 arms). Primary endpoint: Pharmacodynamic effects of CLS001 on the target lesion. Started Apr 2015; status: completed.
02
Drugs
omiganan
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2014-003689-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003689-26.